Recruiting

ICCANImpact of ICCAN on Cancer Treatment Completion and Quality of Life

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT01742143

Conditions

Cancer Patients

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

The Integrated Cancer Care Access Network (ICCAN)

Usual and Customary Group (U&C)

Study Details

Brief summary:

The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

Conditions

Cancer Patients

Study ID

NCT01742143

Start date

Nov, 2012

Status verified date

Aug, 2026

Completion date

Nov, 2027

Anticipated

Primary completion date

Nov, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Participant Inclusion Criteria:

Patient is eligible if he/she is

fluent in English, Spanish, or Mandarin
between the ages of 21-80 years old
cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
planning on remaining in the area for at least 1 year

Clinician is eligible if he/she:

Has an MD or DO degree
Is the treating physician providing care to a patient enrolled to the study

ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:

Is 18 - 85 years of age
Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
Is treated in the NY metropolitan area
Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income < 200% of federal poverty level)
Has English or Spanish proficiency
Agrees to be audio-recorded

ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:

Is 18 - 85 years of age
Has stage II-III TNBC
Treated at MSK Manhattan or OneMSK regional sites
Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income < 200% of federal poverty level)
Has English or Spanish proficiency
Agrees to be audio-recorded

ICCAN-IO process evaluation study team participants only:

Staff member who serves as an Access Facilitator
Agrees to be audio-recorded

CCAN-GBM

Over the age of 18 (per EMR)
Diagnosed with Glioblastoma (per EMR)
Has not yet started radiation and concurrent temozolomide treatment (per EMR)
Has a primary neuro-oncologist at MSK (per EMR)
Will be undergoing radiation at MSK (per EMR)
Treatment plan consists of a 6-week or 3-week (hypofractionated) course of radiation and chemotherapy (per EMR)
Participant or caregiver is fluent in English or Spanish
Planning on remaining in the tri-state area during the 6 weeks or 3 weeks of radiation and chemotherapy (per self-report)
Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance (per EMR or self-report), demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit), and/or requests help with SDOH resources or navigation

Participant Exclusion Criteria:

Patient is ineligible if he/she is:

Diagnosed with Stage IV disease
Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
Has another family member already enrolled in ICCAN (as determined by patient report)

ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:

Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
Participants or family members who are participating in MSK IHCD studies related to social determinants of health

ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:

Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
Participants or family members who are participating in MSK IHCD studies related to social determinants of health at the PI's discretion

ICCAN-GBM

No recurrences - must be newly diagnosed glioblastoma (per EMR)
Patients undergoing different treatment regimens from the 15 fraction/3 week or 30 fraction/6 week course of radiation (i.e. patients undergoing 10 fractions of palliative radiation due to poor functional status) (per EMR)
Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms that require individual treatment) (per EMR or self-report)
Severe cognitive impairment or fluent aphasia as not to understand the assessment measures, interview, or informed consent, without a health care proxy or caregiver that can assist as indicated by clinician or per judgement of study staff. Completion of assessments with the help of caregivers is acceptable. (per EMR or self-report)
Has another family member or household member already enrolled in ICCAN (per self-report)
Already participated in or already completed the ICCAN program (per self-report)

Study Design

Enrollment

347 participants

Anticipated

Interventions and Outcome Measures

Arms

Phase I: Refinement

10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK

Phase II, Arm 1: Usual and Customary Care (U&C)

Participants in this group will receive the same referrals on social and economic resources as ICCAN group.

Phase II, Arm 2: ICCAN-IO

Arm 2 will consist of everything in Arm 1

Interventions

The Integrated Cancer Care Access Network (ICCAN)

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Usual and Customary Group (U&C)

Primary outcome measure

Treatment completion/adherence [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Francesca Gany, MD, MS

646-888-8054

Jennifer Leng, MD, MPH

646-888-4243

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Francesca Gany, MD, MS

646-888-8054

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Fransecsa Gany, MD, MS

646-888-8054

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Francesca Gany, MD, MS

646-888-8054

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Francesca Gany, MD, MS

646-888-8054

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Francesca Gany, MD, MS

646-888-8054

City College of New York (Data Collection AND Data Analysis)

Recruiting

New York, New York, United States, 10031

Contacts

Adriana Espinosa, MD

212-650-8404 aespinosa@ccny.cuny.edu

Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)

Recruiting

New York, New York, United States, 10035

Contacts

Francesca Gany, MD

646-888-8054

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10065

Contacts

Francesca Gany, MD, MS

646-888-8054

Jennifer Leng, MD, MPH

646-888-4243

Principal Investigator:

Francesca Gany, MD, MS

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Recruiting

Rockville Centre, New York, United States, 11553

Contacts

Franscesca Gany, MD, MS

646-888-8054

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Aug 28, 2026

Last verified

Aug, 2026

Keywords

Quality of life
cancer
12-223

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-08-28.